KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Exact Sciences (EXAS) EBITDA Margin (2016 - 2025)

Exact Sciences has reported EBITDA Margin over the past 16 years, most recently at 9.4% for Q4 2025.

  • Quarterly EBITDA Margin rose 11343.0% to 9.4% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 6.35% through Dec 2025, up 3166.0% year-over-year, with the annual reading at 6.35% for FY2025, 3166.0% up from the prior year.
  • EBITDA Margin was 9.4% for Q4 2025 at Exact Sciences, down from 3.0% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 1.09% in Q3 2023 and troughed at 122.84% in Q4 2024.
  • The 5-year median for EBITDA Margin is 15.16% (2024), against an average of 26.05%.
  • Year-over-year, EBITDA Margin tumbled -11235bps in 2024 and then soared 11343bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 46.74% in 2021, then skyrocketed by 54bps to 21.5% in 2022, then skyrocketed by 51bps to 10.49% in 2023, then plummeted by -1071bps to 122.84% in 2024, then skyrocketed by 92bps to 9.4% in 2025.
  • Per Business Quant, the three most recent readings for EXAS's EBITDA Margin are 9.4% (Q4 2025), 3.0% (Q3 2025), and 0.26% (Q2 2025).